Expert Interview
Digging into the TRANSCEND studies for Bristol Myers' Breyanzi (lisocabtagene maraleucel) in follicular and mantle cell lymphoma
Ticker(s): BMYInstitution: Mount Sinai
- Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai.
- Currently manages ~250 patients with CLL and SLL and 70 patients with Hodgkin Lymphoma.
- Research areas of focus include Lymphoma immunotherapy and B-cell receptor signaling inhibitors (e.g. PI3K, mTOR, BTK)
Roughly how many patients with relapsed or refractory Follicular lymphoma and/or refractory B-cell non-Hodgkin lymphoma do you currently manage?
Added By: chanell_adminHow familiar are you with the recent data from the two TRANSCEND studies from Bristol Myers evaluating Breyanzi (lisocabtagene maraleucel) in follicular lymphoma (Phase 2) and mantle cell lymphoma (Phase 1)?
Added By: chanell_adminFor a CD19 CAR T like Breyanzi, where would that fit in, especially now in light of the bispecifics that are coming out? What line of therapy could it be appropriate, do you think?
What is the current standard of care, and how do you see the unmet need in this space and the potential for CAR T?
Once there are multiple CD19 CAR T's approved and an indication, how do you as a provider decide between them?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
